Down regulation of CAII is associated with tumor differentiation and poor prognosis in patients with pancreatic cancer

Recent Developments in Targeting Carbonic Anhydrase IX for Cancer Therapeutics

(2015) Paul C. McDonald et al.   Oncotarget

Carbonic Anhydrase IX as a Target for Designing Novel Anticancer Drugs

(2012) S. M. Monti et al.   CURRENT MEDICINAL CHEMISTRY

Correlation between p53 expression and clinical-pathological characteristics of gastric cancer

(2011) Dragce Radovanovic et al.   Vojnosanitetski Pregled

Low Expression of Claudin-4 is Associated with Poor Prognosis in Esophageal Squamous Cell Carcinoma

(2010) Chang Ohk Sung et al.   ANNALS OF SURGICAL ONCOLOGY

Selective Inhibition of Carbonic Anhydrase IX Decreases Cell Proliferation and Induces Ceramide-Mediated Apoptosis in Human Cancer Cells

(2010) F. Cianchi et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors

(2010) Seppo Parkkila et al.   MODERN PATHOLOGY

Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer

(2009) J. P. Morton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular markers of pancreatic cancer: development and clinical relevance

(2008) Lucia C. Fry et al.   LANGENBECKS ARCHIVES OF SURGERY

Carbonic anhydrases: novel therapeutic applications for inhibitors and activators

(2008) Claudiu T. Supuran   NATURE REVIEWS DRUG DISCOVERY